NEW YORK, April 2, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on INSY, NTLA, ICPT, and ITCI which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, March 29, 2018, US markets saw broad based gains with all
On Thursday, shares in Chandler, Arizona headquartered INSYS Therapeutics Inc. recorded a trading volume of 261,785 shares. The stock ended the session 0.49% lower at $6.04. The stock is trading below its 50-day moving average by 23.71%. Moreover, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have a Relative Strength Index (RSI) of 33.41.
On March 09th, 2018, research firm Piper Jaffray downgraded the Company's stock rating from 'Neutral' to 'Underweight'. Get the full research report on INSY for free by clicking below at:
Cambridge, Massachusetts headquartered Intellia Therapeutics Inc.'s stock closed the day 0.28% lower at $21.09 with a total trading volume of 892,037 shares. The Company's shares have advanced 53.72% over the last twelve months. The stock is trading below its 50-day moving average by 16.81%. Additionally, shares of Intellia Therapeutics, which focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system, have an RSI of 35.09.
On March 08th, 2018, research firm JMP Securities initiated a 'Market Outperform' rating on the Company's stock, with a target price of $76 per share. Free research on NTLA can be accessed at:
Shares in New York headquartered Intercept Pharmaceuticals Inc. recorded a trading volume of 463,977 shares. The stock ended last Thursday's trading session 2.28% higher at $61.52. The Company's shares have advanced 3.00% in the past month. The stock is trading above its 50-day moving average by 0.41%. Furthermore, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics in the US, Europe, and Canada, have an RSI of 45.05. Sign up today for the free research report on ICPT at:
New York headquartered Intra-Cellular Therapies Inc.'s stock finished Thursday's session 2.33% higher at $21.05 with a total trading volume of 242,205 shares. The Company's shares have advanced 37.67% over the previous three months and 28.04% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 6.05% and 30.46%, respectively. Additionally, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases, have an RSI of 47.54. Wall St. Equities' research coverage also includes the downloadable free report on ITCI at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.orgPhone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----insys-therapeutics-intellia-therapeutics-intercept-pharma-and-intra-cellular-therapies-300622519.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...
Beetroot tea is a healthy beverage, which is extremely beneficial for high blood pressure, ...View All